R2 Technologies Inc. ("R2"), the leader in CryoAesthetic™ medical devices, announces that its revolutionary in-office system, Glacial Rx®, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation, is now the first and only dermal cooling system FDA-cleared for general dermabrasion, scar and acne scar revision, and tattoo removal, permanently changing the aesthetics industry.
“This additional FDA clearance is a huge win, and not an easy feat. It took innovation, dedication, time, and resources,” says Tim Holt, R2 Chief Executive Officer. “It couldn’t have been possible without our amazing team and strategic partners. The clearance had an exceptional outcome in which we went from being part of one classification, among hundreds of other devices, to being placed in our very own FDA-issued product code. This is further proof that our product is so novel, it warrants a completely new category.”
“R2 has been at the forefront of the med-esthetics space since inception with its unmatched technology and continues to lead advancements in the industry. We are excited to see the company break boundaries yet again with its latest indication,” says David Present, MD and Cherine Eldumiati Plumaker, R2’s Chairman and Vice Chairman respectively.
In conjunction with the commercial launch, R2 looked within its remarkable team of industry veterans, including the inventors of the Glacial Rx technology, Rox Anderson, MD; Dieter Manstein MD, PhD; and Henry Chan, MD, PhD, to create its newly established Scientific Advisory Board. By continuing to have these highly regarded pioneers as an integral part of the company, R2 stands out amongst the competitive medical aesthetics market as an industry frontrunner.
“With the appointment of our new Scientific Advisory Board, R2 is tapping into years of knowledge and expertise to launch new groundbreaking innovations, develop a superior product pipeline, and leverage technical insights to secure new clinical indications and expansion opportunities,” says Holt.
Launched in March 2021, Glacial Rx’s presence in the U.S. has grown significantly. R2 is continuing to take orders from aesthetic providers who want to offer this revolutionary treatment in-office. To learn more about R2, treatment offerings and providers, visit glacialskin.com and follow the company on LinkedIn.
About R2 Technologies
Headquartered in Silicon Valley, with a recent expansion in Florida and new Miami-based satellite office, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital and Blossom Innovations. In 2019, R2 brought on strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientiﬁc founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Its first innovation, Glacial Rx, was named one of the ‘2021 Launches Doctors are Buzzing About’ by RealSelf, the leading, most trusted source to educate on cosmetic procedures. R2 also won the 2nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital, and mentorship available to tech startups. Since inception, R2 has raised $76M in ﬁnancing.
Linsey Tilbor Rubin